CN103917560B - 双特异性抗‑cxcr7免疫球蛋白单可变结构域 - Google Patents

双特异性抗‑cxcr7免疫球蛋白单可变结构域 Download PDF

Info

Publication number
CN103917560B
CN103917560B CN201280026571.1A CN201280026571A CN103917560B CN 103917560 B CN103917560 B CN 103917560B CN 201280026571 A CN201280026571 A CN 201280026571A CN 103917560 B CN103917560 B CN 103917560B
Authority
CN
China
Prior art keywords
single variable
immunoglobulin single
amino acid
seq
cxcr7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280026571.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103917560A (zh
Inventor
弗朗西斯·德康
达维德·安德列·巴蒂斯特·莫桑-德塔耶
马腾·范罗伊
雷格留斯·勒尔
玛丽亚·冈萨雷斯帕胡埃洛
帕斯卡尔·热拉尔·梅谢尔
马蒂娜·斯密特
卡特林恩·斯托特勒斯
菲利普·范龙帕伊
彼得·万兰德舒特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of CN103917560A publication Critical patent/CN103917560A/zh
Application granted granted Critical
Publication of CN103917560B publication Critical patent/CN103917560B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201280026571.1A 2011-03-28 2012-03-28 双特异性抗‑cxcr7免疫球蛋白单可变结构域 Expired - Fee Related CN103917560B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161468250P 2011-03-28 2011-03-28
US61/468,250 2011-03-28
US201161540272P 2011-09-28 2011-09-28
US61/540,272 2011-09-28
US201261600263P 2012-02-17 2012-02-17
US61/600,263 2012-02-17
PCT/EP2012/055499 WO2012130874A1 (en) 2011-03-28 2012-03-28 Bispecific anti-cxcr7 immunoglobulin single variable domains

Publications (2)

Publication Number Publication Date
CN103917560A CN103917560A (zh) 2014-07-09
CN103917560B true CN103917560B (zh) 2017-05-24

Family

ID=45952494

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280026571.1A Expired - Fee Related CN103917560B (zh) 2011-03-28 2012-03-28 双特异性抗‑cxcr7免疫球蛋白单可变结构域

Country Status (7)

Country Link
US (3) US20150158948A9 (enExample)
EP (1) EP2691418A1 (enExample)
JP (1) JP6181040B2 (enExample)
CN (1) CN103917560B (enExample)
AU (1) AU2012234284B2 (enExample)
CA (1) CA2831415A1 (enExample)
WO (1) WO2012130874A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
WO2014081029A1 (ja) * 2012-11-26 2014-05-30 学校法人近畿大学 抗がん剤による末梢神経障害の予防、治療、または軽減剤
SI3248986T1 (sl) 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
JP2018533620A (ja) * 2015-09-14 2018-11-15 ギャラクシー・バイオテック・リミテッド・ライアビリティ・カンパニーＧａｌａｘｙ Ｂｉｏｔｅｃｈ， ＬＬＣ 血管新生因子に対する高力価のモノクローナル抗体
NO2768984T3 (enExample) 2015-11-12 2018-06-09
AU2016351710B2 (en) * 2015-11-13 2023-08-03 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
WO2017137579A1 (en) * 2016-02-12 2017-08-17 Ablynx Nv Method for the production of immunoglobulin single variable domains
IL263704B2 (en) * 2016-06-23 2024-09-01 Ablynx Nv Improved pharmacokinetic assays for immunoglobulin single variable domains
JP7266611B2 (ja) * 2018-02-26 2023-04-28 アブリンクス・エヌ・フェー ペプチドリンカーをコードする改良されたヌクレオチド配列
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048519A2 (en) * 2006-10-18 2008-04-24 Chemocentryx, Inc. Antibodies that bind cxcr7 epitopes

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
EP0702721B1 (en) 1993-06-09 2001-01-03 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1999042077A2 (en) 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
JP4786793B2 (ja) 1998-03-30 2011-10-05 ノースウエスト バイオセラピューティクス，インコーポレイティド 腫瘍形成におけるｃｘｃｒ−４遺伝子の役割に基く治療的および診断的応用
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US7018812B2 (en) 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2003209059A1 (en) 2002-02-08 2003-09-02 Genetastix Corporation Human monoclonal antibodies against membrane proteins
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
EP1558646A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
ES2385829T3 (es) 2003-08-20 2012-08-01 Ucb Pharma, S.A. Métodos para obtener anticuerpos
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
CA2597717C (en) 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
CA2606222C (en) 2005-04-21 2015-06-23 Chemocentryx, Inc. Reagents that bind ccx-ckr2
US8188223B2 (en) * 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) * 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
CN101321784A (zh) 2005-10-11 2008-12-10 埃博灵克斯股份有限公司 针对egfr和igf－ir的纳米抗体tm和多肽
WO2007055823A2 (en) 2005-10-28 2007-05-18 Multispan, Inc. Gpcr expressing cell lines and antibodies
JP5175207B2 (ja) 2005-11-10 2013-04-03 ケモセントリックス インコーポレーティッド 置換キノロンおよび使用法
WO2007118670A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. Dp-78-like nanobodies
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007285695B2 (en) * 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2663042A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
JP4810411B2 (ja) 2006-11-30 2011-11-09 東京応化工業株式会社 処理装置
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
AU2009273251B2 (en) 2008-07-22 2014-12-18 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
EP2352764B1 (en) * 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
AU2009329501B2 (en) * 2008-12-19 2015-11-26 Ablynx N.V. Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4
WO2010141986A1 (en) * 2009-06-09 2010-12-16 Mabdesign Pty Ltd Novel antibodies and uses therefor
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
WO2011143231A2 (en) 2010-05-10 2011-11-17 The Broad Institute High throughput paired-end sequencing of large-insert clone libraries

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048519A2 (en) * 2006-10-18 2008-04-24 Chemocentryx, Inc. Antibodies that bind cxcr7 epitopes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes;Balabanian K et al.;《Journal of Biological Chemistry》;20051021;第280卷(第42期);第35760-35766页 *

Also Published As

Publication number Publication date
AU2012234284A1 (en) 2013-03-28
JP2014511680A (ja) 2014-05-19
JP6181040B2 (ja) 2017-08-16
US20140227270A1 (en) 2014-08-14
US20180355048A1 (en) 2018-12-13
US20140178390A1 (en) 2014-06-26
CN103917560A (zh) 2014-07-09
EP2691418A1 (en) 2014-02-05
AU2012234284B2 (en) 2015-10-08
WO2012130874A1 (en) 2012-10-04
US20150158948A9 (en) 2015-06-11
CA2831415A1 (en) 2012-10-04
US9994639B2 (en) 2018-06-12

Similar Documents

Publication Publication Date Title
CN103917560B (zh) 双特异性抗‑cxcr7免疫球蛋白单可变结构域
US9758584B2 (en) Biological materials related to CXCR7
CN102906118B (zh) 与her3相关的生物材料
US10100110B2 (en) Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN103889451B (zh) 与C-Met相关的生物物质
EP2621953B1 (en) Biological materials related to c-met
CA2834907C (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
JP6034023B2 (ja) Ｃｘｃｒ４及び他のｇｐｃｒに指向性を有するアミノ酸配列及びそれを含む化合物
JP5823871B2 (ja) 血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US10618964B2 (en) Nanobody against IL-6R
JP2009529339A (ja) Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド
CN101611056A (zh) 能够结合于血清蛋白的肽
JP2011516520A (ja) Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
CN103328512A (zh) Cxcr2结合多肽
WO2011083140A1 (en) Immunoglobulin single variable domain directed against human cxcr4
WO2010142551A2 (en) Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
AU2008252854A1 (en) Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
WO2009135953A2 (en) Amino acid sequences directed against integrins and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170524